Literature DB >> 17043755

[Stenting of the SFA--indications, techniques, results].

J Rieger1, M Treitl, M Reiser, V Ruppert.   

Abstract

Aggressive risk factor modification, change of eating habits, exercise programs, and forceful antiplatelet therapy are the most important tools for the treatment of PAOD in symptomatic patients suffering from intermittent claudication. There are however no guidelines for revascularization at this stage. Endovascular treatment has been increasingly utilized over the last decade and increasingly displaced vascular surgery. Amongst numerous endovascular techniques beside PTA, stents meanwhile play the most important role due to constant technical progress. Results regarding the rate of restenosis or patency rates still remain worse compared to other vascular beds. This paper gives a review over recent results, currently available stent techniques, and possible indications for the endovascular therapy of an artery, which has turned out to be the biggest ordeal for material and construction of stents.

Entities:  

Mesh:

Year:  2006        PMID: 17043755     DOI: 10.1007/s00117-006-1425-0

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  25 in total

Review 1.  Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC).

Authors: 
Journal:  Int Angiol       Date:  2000-03       Impact factor: 2.789

Review 2.  Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Section B: intermittent claudication.

Authors: 
Journal:  Eur J Vasc Endovasc Surg       Date:  2000-06       Impact factor: 7.069

3.  Remote superficial femoral artery endarterectomy and distal aSpire stenting: multicenter medium-term results.

Authors:  David Rosenthal; John D Martin; Peter J Schubart; Eric D Wellons; Frederick W Shuler; Adam B Levitt
Journal:  J Vasc Surg       Date:  2004-07       Impact factor: 4.268

4.  In vivo MR angiographic quantification of axial and twisting deformations of the superficial femoral artery resulting from maximum hip and knee flexion.

Authors:  Christopher P Cheng; Nathan M Wilson; Richard L Hallett; Robert J Herfkens; Charles A Taylor
Journal:  J Vasc Interv Radiol       Date:  2006-06       Impact factor: 3.464

5.  Long-term results with the Palmaz stent in the superficial femoral artery.

Authors:  P Bergeron; J J Pinot; V Poyen; H Benichou; P Khanoyan; P Rudondy; Y Wang; S Chiarandini; R el Hussein; R Rieu
Journal:  J Endovasc Surg       Date:  1995-05

6.  Prevalence and clinical impact of stent fractures after femoropopliteal stenting.

Authors:  Dierk Scheinert; Susanne Scheinert; Jacqueline Sax; Christopher Piorkowski; Sven Bräunlich; Matthias Ulrich; Giancarlo Biamino; Andrej Schmidt
Journal:  J Am Coll Cardiol       Date:  2005-01-18       Impact factor: 24.094

7.  Long-term results with a Palmaz stent in the femoropopliteal arteries.

Authors:  P Chatelard; C Guibourt
Journal:  J Cardiovasc Surg (Torino)       Date:  1996-06       Impact factor: 1.888

8.  Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery.

Authors:  Martin Schillinger; Schila Sabeti; Christian Loewe; Petra Dick; Jasmin Amighi; Wolfgang Mlekusch; Oliver Schlager; Manfred Cejna; Johannes Lammer; Erich Minar
Journal:  N Engl J Med       Date:  2006-05-04       Impact factor: 91.245

9.  Vascular inflammation and percutaneous transluminal angioplasty of the femoropopliteal artery: association with restenosis.

Authors:  Martin Schillinger; Markus Exner; Wolfgang Mlekusch; Helmut Rumpold; Ramazanali Ahmadi; Schila Sabeti; Markus Haumer; Oswald Wagner; Erich Minar
Journal:  Radiology       Date:  2002-10       Impact factor: 11.105

10.  Palmaz stent placement in iliac and femoropopliteal arteries: primary and secondary patency in 310 patients with 2-4-year follow-up.

Authors:  M Henry; M Amor; G Ethevenot; I Henry; C Amicabile; R Beron; B Mentre; M Allaoui; N Touchot
Journal:  Radiology       Date:  1995-10       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.